IL-2-dependent HTLV-I-infected T cells escape from non-specific, MHC-unrestricted cellular cytotoxicity. 1994

H Plotnicky, and D Cyblat, and J C Vernant, and C Desgranges
Unité de Recherche sur les Hépatites, SIDA et Rétrovirus Humains, INSERM U271, Lyon, France.

The susceptibility of NK cell-mediated cytolysis was compared between 5 human HTLV-I-transformed T cell lines and 10 newly established IL-2-dependent HTLV-I-infected lines. None of the cell lines were killed after 4 hr incubation with normal PBMC. However, after 20 hr, 3 HTLV-I-transformed lines were significantly lysed. All the HTLV-I-infected lines, except 2, weakly inhibited the NK cell-mediated lysis of K562 targets. They showed a reduced ability to bind normal PBMC as compared with control NK-sensitive T cell lines. The IL-2-dependent lines remained unaffected by PBMC from HTLV-I-infected individuals, including the autologous donors. In contrast to the HTLV-I-transformed lines, they were weakly lysed or not lysed at all by LAK cells and only 5 were killed by ADCC with HTLV-I+ sera and normal PBMC. Taken together, the results show that IL-2-dependent HTLV-I-infected T cells strongly resist NK cell-mediated cytolysis at a post-binding level and suggest that such cells may escape in vivo from non-specific, MHC-unrestricted cellular cytotoxicity.

UI MeSH Term Description Entries
D007376 Interleukin-2 A soluble substance elaborated by antigen- or mitogen-stimulated T-LYMPHOCYTES which induces DNA synthesis in naive lymphocytes. IL-2,Lymphocyte Mitogenic Factor,T-Cell Growth Factor,TCGF,IL2,Interleukin II,Interleukine 2,RU 49637,RU-49637,Ro-23-6019,Ro-236019,T-Cell Stimulating Factor,Thymocyte Stimulating Factor,Interleukin 2,Mitogenic Factor, Lymphocyte,RU49637,Ro 23 6019,Ro 236019,Ro236019,T Cell Growth Factor,T Cell Stimulating Factor
D007694 Killer Cells, Natural Bone marrow-derived lymphocytes that possess cytotoxic properties, classically directed against transformed and virus-infected cells. Unlike T CELLS; and B CELLS; NK CELLS are not antigen specific. The cytotoxicity of natural killer cells is determined by the collective signaling of an array of inhibitory and stimulatory CELL SURFACE RECEPTORS. A subset of T-LYMPHOCYTES referred to as NATURAL KILLER T CELLS shares some of the properties of this cell type. NK Cells,Natural Killer Cells,Cell, NK,Cell, Natural Killer,Cells, NK,Cells, Natural Killer,Killer Cell, Natural,NK Cell,Natural Killer Cell
D008285 Major Histocompatibility Complex The genetic region which contains the loci of genes which determine the structure of the serologically defined (SD) and lymphocyte-defined (LD) TRANSPLANTATION ANTIGENS, genes which control the structure of the IMMUNE RESPONSE-ASSOCIATED ANTIGENS, HUMAN; the IMMUNE RESPONSE GENES which control the ability of an animal to respond immunologically to antigenic stimuli, and genes which determine the structure and/or level of the first four components of complement. Histocompatibility Complex,Complex, Histocompatibility,Complex, Major Histocompatibility,Complices, Histocompatibility,Complices, Major Histocompatibility,Histocompatibility Complex, Major,Histocompatibility Complices,Histocompatibility Complices, Major,Major Histocompatibility Complices
D010641 Phenotype The outward appearance of the individual. It is the product of interactions between genes, and between the GENOTYPE and the environment. Phenotypes
D002460 Cell Line Established cell cultures that have the potential to propagate indefinitely. Cell Lines,Line, Cell,Lines, Cell
D003602 Cytotoxicity, Immunologic The phenomenon of target cell destruction by immunologically active effector cells. It may be brought about directly by sensitized T-lymphocytes or by lymphoid or myeloid "killer" cells, or it may be mediated by cytotoxic antibody, cytotoxic factor released by lymphoid cells, or complement. Tumoricidal Activity, Immunologic,Immunologic Cytotoxicity,Immunologic Tumoricidal Activities,Immunologic Tumoricidal Activity,Tumoricidal Activities, Immunologic
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000920 Antibody-Dependent Cell Cytotoxicity The phenomenon of antibody-mediated target cell destruction by non-sensitized effector cells. The identity of the target cell varies, but it must possess surface IMMUNOGLOBULIN G whose Fc portion is intact. The effector cell is a "killer" cell possessing Fc receptors. It may be a lymphocyte lacking conventional B- or T-cell markers, or a monocyte, macrophage, or polynuclear leukocyte, depending on the identity of the target cell. The reaction is complement-independent. ADCC,Cytotoxicity, Antibody-Dependent Cell,Cell Cytoxicity, Antibody-Dependent,Antibody Dependent Cell Cytotoxicity,Antibody-Dependent Cell Cytotoxicities,Antibody-Dependent Cell Cytoxicities,Antibody-Dependent Cell Cytoxicity,Cell Cytotoxicities, Antibody-Dependent,Cell Cytotoxicity, Antibody-Dependent,Cell Cytoxicities, Antibody-Dependent,Cell Cytoxicity, Antibody Dependent,Cytotoxicities, Antibody-Dependent Cell,Cytotoxicity, Antibody Dependent Cell,Cytoxicities, Antibody-Dependent Cell,Cytoxicity, Antibody-Dependent Cell
D013601 T-Lymphocytes Lymphocytes responsible for cell-mediated immunity. Two types have been identified - cytotoxic (T-LYMPHOCYTES, CYTOTOXIC) and helper T-lymphocytes (T-LYMPHOCYTES, HELPER-INDUCER). They are formed when lymphocytes circulate through the THYMUS GLAND and differentiate to thymocytes. When exposed to an antigen, they divide rapidly and produce large numbers of new T cells sensitized to that antigen. T Cell,T Lymphocyte,T-Cells,Thymus-Dependent Lymphocytes,Cell, T,Cells, T,Lymphocyte, T,Lymphocyte, Thymus-Dependent,Lymphocytes, T,Lymphocytes, Thymus-Dependent,T Cells,T Lymphocytes,T-Cell,T-Lymphocyte,Thymus Dependent Lymphocytes,Thymus-Dependent Lymphocyte
D015458 Leukemia, T-Cell A malignant disease of the T-LYMPHOCYTES in the bone marrow, thymus, and/or blood. Leukemia, Lymphocytic, T-Cell,Lymphocytic Leukemia, T-Cell,T-Cell Leukemia,T-Lymphocytic Leukemia,Leukemia, Lymphocytic, T Cell,T Lymphocytic Leukemia,Leukemia, T Cell,Leukemia, T Lymphocytic,Leukemia, T-Cell Lymphocytic,Leukemia, T-Lymphocytic,Leukemias, T Lymphocytic,Leukemias, T-Cell,Leukemias, T-Cell Lymphocytic,Leukemias, T-Lymphocytic,Lymphocytic Leukemia, T,Lymphocytic Leukemia, T Cell,Lymphocytic Leukemias, T,Lymphocytic Leukemias, T-Cell,T Cell Leukemia,T Lymphocytic Leukemias,T-Cell Leukemias,T-Cell Lymphocytic Leukemia,T-Cell Lymphocytic Leukemias,T-Lymphocytic Leukemias

Related Publications

H Plotnicky, and D Cyblat, and J C Vernant, and C Desgranges
January 1992, Biotherapy (Dordrecht, Netherlands),
H Plotnicky, and D Cyblat, and J C Vernant, and C Desgranges
February 1988, Immunology,
H Plotnicky, and D Cyblat, and J C Vernant, and C Desgranges
February 1987, Journal of immunology (Baltimore, Md. : 1950),
H Plotnicky, and D Cyblat, and J C Vernant, and C Desgranges
May 2011, Proceedings of the National Academy of Sciences of the United States of America,
H Plotnicky, and D Cyblat, and J C Vernant, and C Desgranges
February 1990, Acta paediatrica Japonica : Overseas edition,
H Plotnicky, and D Cyblat, and J C Vernant, and C Desgranges
June 1991, Clinical and experimental immunology,
H Plotnicky, and D Cyblat, and J C Vernant, and C Desgranges
September 2000, Blood,
H Plotnicky, and D Cyblat, and J C Vernant, and C Desgranges
May 1992, Journal of immunology (Baltimore, Md. : 1950),
H Plotnicky, and D Cyblat, and J C Vernant, and C Desgranges
January 1987, Progress in clinical and biological research,
H Plotnicky, and D Cyblat, and J C Vernant, and C Desgranges
June 1997, European journal of immunology,
Copied contents to your clipboard!